Targeting IGF2BP1 Enhances Immune Checkpoint Therapy in High-grade Serous Ovarian Cancer
Non-coding RNA profiling · human · 26 samples
- What it is
- Non-coding RNA profilingLevels of RNAs that do not code for proteins, such as miRNA or lncRNA.
- Organism
- Homo sapiens (human)
- Topic
- Ovarian cancerThis series is part of our curated briefing on it.
- Samples
- 26 samples: 10 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancerSignal transduction and targeted therapy · 2025
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE234708_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
Also filed as BioProject PRJNA982792 and SRA study SRP442896. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 26 samples.
How we read this: 10 replicated groups read from 26 sample titles; they account for 26 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM7473564 DMSO, Killing, ES2, Rep 1 DMSO, Killing, ES2,
- GSM7473565 DMSO, Killing, ES2, Rep 2 DMSO, Killing, ES2,
- GSM7473566 BTYNB-10pre_Killing_ES2, Rep 1 BTYNB-10pre_Killing_ES2,
- GSM7473567 BTYNB-10pre_Killing_ES2, Rep 2 BTYNB-10pre_Killing_ES2,
- GSM7473568 DMSO_Killing_Tcells, Rep 1 DMSO_Killing_Tcells,
- GSM7473569 DMSO_Killing_Tcells, Rep 2 DMSO_Killing_Tcells,
- GSM7473570 BTYNB-10pre_Killing_Tcells, Rep 1 BTYNB-10pre_Killing_Tce…
- GSM7473571 BTYNB-10pre_Killing_Tcells, Rep 2 BTYNB-10pre_Killing_Tce…
- GSM7473572 ES-2 cells, input, Rep 1 ES-2 cells, input,
- GSM7473573 ES-2 cells, input, Rep 2 ES-2 cells, input,
- GSM7473574 ES-2 cells, input, Rep 3 ES-2 cells, input,
- GSM7473575 ES-2 cells,MS2 control RNA, Rep 1 ES-2 cells,MS2 control …
- GSM7473576 ES-2 cells,MS2 control RNA, Rep 2 ES-2 cells,MS2 control …
- GSM7473577 ES-2 cells,MS2 control RNA, Rep 3 ES-2 cells,MS2 control …
- GSM7473578 ES-2 cells,PD-L1 3'UTR, Rep 1 ES-2 cells,PD-L1 3'UTR,
- GSM7473579 ES-2 cells,PD-L1 3'UTR, Rep 2 ES-2 cells,PD-L1 3'UTR,
- GSM7473580 ES-2 cells,PD-L1 3'UTR, Rep 3 ES-2 cells,PD-L1 3'UTR,
- GSM8677732 ES-2 cells with PBMCs, DMSO, treatment 1 ES-2 cells with PBMCs, …
- GSM8677733 ES-2 cells with PBMCs, DMSO, treatment 2 ES-2 cells with PBMCs, …
- GSM8677734 ES-2 cells with PBMCs, DMSO, treatment 3 ES-2 cells with PBMCs, …
- GSM8677735 ES-2 cells with PBMCs, CUB, treatment 1 ES-2 cells with PBMCs, …
- GSM8677736 ES-2 cells with PBMCs, CUB, treatment 2 ES-2 cells with PBMCs, …
- GSM8677737 ES-2 cells with PBMCs, CUB, treatment 3 ES-2 cells with PBMCs, …
- GSM8677738 ES-2 cells with PBMCs, BTYNB, treatment 1 ES-2 cells with PBMCs, …
- GSM8677739 ES-2 cells with PBMCs, BTYNB, treatment 2 ES-2 cells with PBMCs, …
- GSM8677740 ES-2 cells with PBMCs, BTYNB, treatment 3 ES-2 cells with PBMCs, …
- GSE268514 Integrative genomic analysis of Korean high-grade serous ovarian cancer 161 samples same disease briefing · shares high-grade, ovarian, serous
- GSE154600 Multi-omic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma 5 samples same disease briefing · shares high-grade, ovarian, serous
- GSE57477 Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes 72 samples same disease briefing · shares ovarian, serous
- GSE314300 Rb CUT&RUN profiling in ovarian cancer cell lines following CDK2 inhibitor treatment 10 samples same disease briefing · shares ovarian
- GSE135242 Hi-C identifies structural variation associated with resistance in paired patient-derived ovarian cancer models 8 samples same disease briefing · shares ovarian
- GSE311212 Transcriptomic profiling in human ovarian cancer cell line OVCAR-3 following CDK2 inhibitor treatment 6 samples same disease briefing · shares ovarian
- GSE128098 TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target 4 samples same disease briefing · shares ovarian
- GSE28330 Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents 107 samples same disease briefing
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.